VanEck Vectors Coal ETF
Limited financial coverage for KOL.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Range $60 – $60
Price Chart
About the company
The VanEck Vectors Coal ETF (KOL) is designed to closely mirror, before accounting for fees and expenses, the total return performance (both price appreciation and income generation) of the MVIS® Global Coal Index. To achieve this objective, the fund typically commits at least 80% of its overall assets to the component securities that constitute its benchmark index. The MVIS® Global Coal Index encompasses companies operating within the global coal sector that generate a minimum of 50% of their income from various coal-related operations.
- IPO
- 2008
Get TickerSpark's AI analysis on KOL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.33M
- Div Yield
- 3.42%
- 52W High
- $99.33
- 52W Low
- $54.10
- 50D MA
- $94.92
- 200D MA
- $81.72
- Beta
- 1.18
- RSI (14)
- 65
- Avg Volume
- 8.23K
No earnings-call transcripts are available for KOL yet.
- Free Float
- 0.0%
- Shares Outstanding
- 372.25K
- Float Shares
- 0
Our KOL coverage
Recent articles, reports, and earnings notes.
No research on KOL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KOL report →vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
globenewswire.com · Oct 6
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
globenewswire.com · Sep 30
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
globenewswire.com · Sep 28
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
globenewswire.com · Sep 17
Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference
globenewswire.com · Sep 16
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
businesswire.com · Sep 8
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
globenewswire.com · Aug 24
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
globenewswire.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.